# A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants

> **NCT05607537** · PHASE1 · COMPLETED · sponsor: **Eisai Limited** · enrollment: 15 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** E7386 Tablet
- **DRUG:** (14C)E7386 Capsule
- **DRUG:** (14C)E7386

## Key facts

- **NCT ID:** NCT05607537
- **Lead sponsor:** Eisai Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-17
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05607537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05607537, "A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT05607537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*